Section Arrow
Quote
INDP.NASDAQ
- Indaptus Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/17 16:43 EDT
After Hours
Last
 11.52
+0.21 (+1.86%)
Bid
10.95
Ask
11.96
High 11.52 
Low 11.23 
Volume 56 
Regular Hours
Last
 11.31
-0.54 (-4.56%)
Day High 
12.23 
Prev. Close
11.85 
1-M High
19.9136 
Volume 
13.28K 
Bid
10.95
Ask
11.96
Day Low
11.2 
Open
12.23 
1-M Low
7.5628 
Market Cap 
6.79M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.86 
20-SMA 11.37 
50-SMA 10.88 
52-W High 66.64 
52-W Low 7.5628 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-41.44/-25.20
Enterprise Value
6.79M
Balance Sheet
Book Value Per Share
4.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.1.05+0.15+16.67%0.84PE
After Hours 1.1 +0.05 +4.76%
ABPAbpro Holdings Inc0.1962-0.022-10.08%-- 
After Hours 0.1957 -0.0005 -0.25%
NCNANuCana plc0.0468-0.0034-6.77%-- 
After Hours 0.0469 +0.0001 +0.21%
ATNF180 Life Sciences Corp1.83+0.9497+107.88%0.11PE
After Hours 1.71 -0.12 -6.56%
MRKRMarker Therapeutics1.92+0.32+20.00%-- 
After Hours 1.92 0 0.00%
Quotes are at least 15-min delayed：2025/07/17 16:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.